The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small-cell Lung Cancer

Baseline Edmonton Symptom Assessment System and Survival in Metastatic Renal Cell Carcinoma

“…Our results are consistent with those emerging from other studies exploring the role of symptom burden and quality-of-life metrics in clinical oncology 8 .…”

“…It has since been validated for use in patients with cancer 6,7 . More recently, the esas score has been demonstrated to predict for outcomes in patients with non-small-cell lung cancer, with a greater symptom burden being associated with decreased survival 8 . To our knowledge, the esas has not been used for prognostication in patients receiving active systemic therapy for advanced kidney cancer.…”

Are Clinical Trial Eligibility Criteria an Accurate Reflection of a Real-World Population of Advanced Non-Small-Cell Lung Cancer Patients?

“…The limited data led to the small number of eligibility criteria used for the study scenarios, unlike the case of a real clinical trial. Given its retrospective nature, our study could not provide prospective data about quality of life and treatment-related toxicity; however, for this same cohort of patients, we were able to show that scores from the Edmonton Symptom Assessment System were able to predict survival, as published in a separate paper 41 . Furthermore, our cohort did not include hospitalized patients, and it largely included patients managed before reflexive molecular profiling for EGFR mutations and ALK translocations became a standard of care.…”

The Pain Prevalence, Characteristics and Related Factors of Non-Small Cell Lung Cancer (NSCLC) Referral to Palliative Care Service

“…Over 90% of patients with advanced lung cancer experienced pain and fatigue in another research [12]. In another study of patients with NSCLC, pain was reported to be only 37% [13]. These studies were quite heterogeneous with differences in sample sizes, cancer stage and clinical variables, making it di cult to ascertain the exact prevalence of pain among advanced lung cancer patients.…”

“…CP continued to affect 33% of cancer patients even after anti-pain treatment. Even after receiving pain relief treatment, 30% of patients still suffer from cancer pain [3,4]. During the whole course of cancer disease, patients are more or less disturbed by pain.…”